What is Sino Biopharmaceutical Limited's contact information?

Sino Biopharmaceutical Limited's contact information: info@sino-biopharm.com, +86 10 59257399, +852 2802 9886, +85228029886.

How many employees does Sino Biopharmaceutical Limited have?

Sino Biopharmaceutical Limited has 29 employees.

What industry does Sino Biopharmaceutical Limited belong to?

Sino Biopharmaceutical Limited is in the industry of: Pharmaceuticals, Pharmaceutical Manufacturing, Internet.

What are Sino Biopharmaceutical Limited's official social media profiles?

Sino Biopharmaceutical Limited Linkedin Page Sino Biopharmaceutical Limited Twitter Page

What tech stack does Sino Biopharmaceutical Limited use?

Some of the popular technologies that Sino Biopharmaceutical Limited uses are: Google Workspace, Google Workspace.

What are Sino Biopharmaceutical Limited's office addresses?

Sino Biopharmaceutical Limited has 3 known office addresses: 北京市朝阳区光华路10号正大中心北塔45层香港湾仔港湾道1号会展广场办公大楼41楼09室 1Harbour Road Hong Kong, Hong Kong Island, HK.

What is Sino Biopharmaceutical Limited's estimated annual revenue?

Sino Biopharmaceutical Limited's revenue is $3,500,000,000

What is Sino Biopharmaceutical Limited's open headcount?

Sino Biopharmaceutical Limited has no job postings yet.

What is the number of ad campaigns for Sino Biopharmaceutical Limited?

Sino Biopharmaceutical Limited has no advertisements yet.

What is the number of recent news articles about Sino Biopharmaceutical Limited?

Sino Biopharmaceutical Limited has 4 news articles.

Sino Biopharmaceutical Limited - Pubrio Company Profile & Intent

Sino Biopharmaceutical Limited

Hong Kong · Pharmaceutical Manufacturing

Pharmaceuticals

Pharmaceutical Manufacturing

Internet

Sino Biopharmaceutical Limited and its subsidiaries are the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain of pharmaceutical R&D platforms, intelligent production and strong sales systems. Its product offerings include a variety of biological drugs and chemical drugs, and it occupies an advantageous position in many potential therapeutic fields such as liver disease, tumors, cardiovascular and cerebrovascular diseases, orthopedics, digestive system, immune and respiratory diseases.

Company Insights

prnasia.com · partners_with · one week ago

Open news

Sino Biopharmaceutical licenses Rovalpituzumab to Sanofi

Sino Biopharmaceutical grants Sanofi exclusive global rights for Rovalpituzumab, a first-in-class JAK/ROCK inhibitor, in a deal worth up to $1.53 billion.

Sanofi

Sino Biopharmaceutical Limited

prnasia.com · partners_with · 2025-11-10

Open news

Sino Biopharm and MediTrust Health partner for drug-insurance integration

Sino Biopharm and MediTrust Health partner to explore drug-insurance integration, aiming to improve patient access to affordable, innovative medicines in China.

Sino Biopharmaceutical Limited

镁信健康

prnasia.com · receives_award · 2025-09-01

Open news

Zongertinib approved in China for HER2-mutated NSCLC

Zongertinib, jointly promoted by Boehringer Ingelheim and Sino Biopharmaceutical, approved in China for HER2-mutated advanced NSCLC patients who received prior systemic therapy.

World Health Organization

New England Journal Of Medicine

Headspace Study

American Association For Cancer Research

Sino Biopharmaceutical Limited

Boehringer Ingelheim

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin option investors bet on downside despite price rise

Bitcoin ETF and crypto-holding firms are buying put options to hedge against potential price drops below $60,000, despite recent price increases.

Coindesk

Deribit

khgames.co.kr · is_developing · one week ago

Open news

Bitcoin's 'Death Cross' Appears: Future Trends?

Bitcoin chart shows 'death cross' pattern, historically preceding major price drops. Despite this, ETFs see $1 billion inflow and long-term investors continue accumulating.

Coindesk

Upbit Singapore

coinreaders.com · launches · one week ago

Open news

JPMorgan: Crypto Market Structure Act likely to pass mid-year

JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.

Coindesk

J.P. Morgan

Get full access to view complete information

1 - 4 of 4

Frequently Asked Questions Regarding Sino Biopharmaceutical Limited

Company Overview

2000

Founded

Pharmaceutical Manufacturing

Industry

Hong Kong

Location

1,562,393

Ranking

29 employees

Size

Similar Companies

Get full access to view complete information